UMECRINE COGNITION

Umecrine Cognition is a Swedish clinical-stage pharmaceutical company developing a novel class of drugs to treat neurological disorders of the brain... Umecrine Cognition is led by a group of people with extensive experience in drug development and commercialization, with prior leadership positions in the Astra corporation, Medivir, Biovitrum (currently Sobi), Karo Bio, as well as regulatory experience from the Swedish MPA... Umecrine Cognition is developing a completely new type of drug for neurological disorders in the brain that can occur as a result of a number of underlying diseases and lead to severely reduced cognition and alertness.

Also known as: Umecrine Cognition AB

Registration numbers: 556698-3655 (W)

Primary location: Solna Sweden